In honor of March Madness, The Motley Fool's health-care team assembled their own bracket consisting of the 16 largest and best pharmaceutical and biotech stocks on the market. The series gets under way with a tough matchup between AbbVie (NYSE: ABBV ) , Abbott's recently spun-off pharmaceutical division, and Big Pharma giant GlaxoSmithKline (NYSE: GSK ) . To learn the bull and bear cases for each stock -- and to see which stock will move on to the Elite Eight -- watch the following video.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.